Menu
Back to User profile » Dr Marty Hinz
Papers published by Dr Marty Hinz:
Parkinson’s Disease-Associated Melanin Steal [Retraction]
Hinz M, Stein A, Cole T
Neuropsychiatric Disease and Treatment 2021, 17:733-734
Published Date: 3 March 2021
Parkinson’s Disease: Carbidopa, Nausea, and Dyskinesia [Retraction]
Hinz M, Stein A, Cole T
Clinical Pharmacology: Advances and Applications 2021, 13:43-44
Published Date: 3 March 2021
The Parkinson’s Disease Death Rate: Carbidopa and Vitamin B6 [Retraction]
Hinz M, Stein A, Cole T
Clinical Pharmacology: Advances and Applications 2021, 13:41-42
Published Date: 3 March 2021
Administration of Supplemental L-Tyrosine with Phenelzine: a Clinical Literature Review [Retraction]
Hinz M, Stein A, Cole T, Ryan P
Clinical Pharmacology: Advances and Applications 2021, 13:39-40
Published Date: 3 March 2021
5-HTP Efficacy and Contraindications [Retraction]
Hinz M, Stein A, Uncini T
Neuropsychiatric Disease and Treatment 2021, 17:731-732
Published Date: 3 March 2021
Validity of Urinary Monoamine Assay Sales Under the “Spot Baseline Urinary Neurotransmitter Testing Marketing Model” [Retraction]
Hinz M, Stein A, Uncini T
International Journal of Nephrology and Renovascular Disease 2021, 14:65-66
Published Date: 3 March 2021
Monoamine Depletion by Reuptake Inhibitors [Retraction]
Hinz M, Stein A, Uncini T
Drug, Healthcare and Patient Safety 2020, 12:269-270
Published Date: 16 December 2020
The Discrediting of the Monoamine Hypothesis [Retraction]
Hinz M, Stein A, Uncini T
International Journal of General Medicine 2020, 13:1547-1548
Published Date: 16 December 2020
Amino Acid-Responsive Crohn’s Disease: A Case Study [Retraction]
Stein A, Hinz M, Uncini T
Clinical and Experimental Gastroenterology 2020, 13:589-590
Published Date: 16 December 2020
A Pilot Study Differentiating Recurrent Major Depression from Bipolar Disorder Cycling on the Depressive Pole [Retraction]
Hinz M, Stein A, Uncini T
Neuropsychiatric Disease and Treatment 2020, 16:3129-3130
Published Date: 16 December 2020
The Dual-Gate Lumen Model of Renal Monoamine Transport [Retraction]
Hinz M, Stein A, Uncini T
Neuropsychiatric Disease and Treatment 2020, 16:3133-3134
Published Date: 16 December 2020
Parkinson’s Disease Managing Reversible Neurodegeneration [Retraction]
Hinz M, Stein A, Cole T, McDougall B, Westaway M
Neuropsychiatric Disease and Treatment 2020, 16:3125-3126
Published Date: 16 December 2020
Amino Acid Management of Parkinson’s Disease: a Case Study [Retraction]
Hinz M, Stein A, Uncini T
International Journal of General Medicine 2020, 13:1545-1546
Published Date: 16 December 2020
Urinary Neurotransmitter Testing: Considerations of Spot Baseline Norepinephrine and Epinephrine [Retraction]
Hinz M, Stein A, Uncini T
Research and Reports in Urology 2020, 12:659-660
Published Date: 16 December 2020
Neurotransmitter Testing of the Urine: a Comprehensive Analysis [Retraction]
Hinz M, Stein A, Trachte G, Uncini T
Research and Reports in Urology 2020, 12:661-662
Published Date: 16 December 2020
Management of L-Dopa Overdose in the Competitive Inhibition State [Retraction]
Hinz M, Stein A, Cole T
Drug, Healthcare and Patient Safety 2020, 12:271-272
Published Date: 16 December 2020
Relative Nutritional Deficiencies Associated with Centrally Acting Monoamines [Retraction]
Hinz M, Stein A, Uncini T
International Journal of General Medicine 2020, 13:1549-1550
Published Date: 16 December 2020
APRESS: Apical Regulatory Super System, Serotonin, and Dopamine Interaction [Retraction]
Hinz M, Stein A, Uncini T
Neuropsychiatric Disease and Treatment 2020, 16:3123-3124
Published Date: 16 December 2020
Treatment of Attention Deficit Hyperactivity Disorder with Monoamine Amino Acid Precursors and Organic Cation Transporter Assay Interpretation [Retraction]
Hinz M, Stein A, Neff R, Weinberg R, Uncini T
Neuropsychiatric Disease and Treatment 2020, 16:3131-3132
Published Date: 16 December 2020
Parkinson’s Disease Managing Reversible Neurodegeneration [Expression of Concern]
Hinz M, Stein A, Cole T, McDougall B, Westaway M
Neuropsychiatric Disease and Treatment 2020, 16:1061-1062
Published Date: 23 April 2020
Parkinson’s Disease-Associated Melanin Steal [Expression of Concern]
Hinz M, Stein A, Cole T
Neuropsychiatric Disease and Treatment 2020, 16:1063-1064
Published Date: 23 April 2020
Parkinson’s Disease: Carbidopa, Nausea, and Dyskinesia [Expression of Concern]
Hinz M, Stein A, Cole T
Clinical Pharmacology: Advances and Applications 2020, 12:45-46
Published Date: 23 April 2020
The Parkinson’s Disease Death Rate: Carbidopa and Vitamin B6 [Expression of Concern]
Hinz M, Stein A, Cole T
Clinical Pharmacology: Advances and Applications 2020, 12:43-44
Published Date: 23 April 2020
Management of L-Dopa Overdose in the Competitive Inhibition State [Expression of Concern]
Hinz M, Stein A, Cole T
Drug, Healthcare and Patient Safety 2020, 12:59-60
Published Date: 23 April 2020
APRESS: Apical Regulatory Super System, Serotonin and Dopamine Interaction [Expression of Concern]
Hinz M, Stein A, Uncini T
Neuropsychiatric Disease and Treatment 2020, 16:1071-1072
Published Date: 23 April 2020
Administration of Supplemental L-Tyrosine with Phenelzine: A Clinical Literature Review [Expression of Concern]
Hinz M, Stein A, Cole T, Ryan P
Clinical Pharmacology: Advances and Applications 2020, 12:47-48
Published Date: 23 April 2020
5-HTP Efficacy and Contraindications [Expression of Concern]
Hinz M, Stein A, Uncini T
Neuropsychiatric Disease and Treatment 2020, 16:1059-1060
Published Date: 23 April 2020
Relative Nutritional Deficiencies Associated with Centrally Acting Monoamines [Expression of Concern]
Hinz M, Stein A, Uncini T
International Journal of General Medicine 2020, 13:143-144
Published Date: 23 April 2020
The Discrediting of the Monoamine Hypothesis [Expression of Concern]
Hinz M, Stein A, Uncini T
International Journal of General Medicine 2020, 13:141-142
Published Date: 23 April 2020
Monoamine Depletion by Reuptake Inhibitors [Expression of Concern]
Hinz M, Stein A, Uncini T
Drug, Healthcare and Patient Safety 2020, 12:57-58
Published Date: 23 April 2020
Validity of Urinary Monoamine Assay Sales Under the “Spot Baseline Urinary Neurotransmitter Testing Marketing Model” [Expression of Concern]
Hinz M, Stein A, Uncini T
International Journal of Nephrology and Renovascular Disease 2020, 13:73-74
Published Date: 23 April 2020
Urinary Neurotransmitter Testing: Considerations of Spot Baseline Norepinephrine and Epinephrine [Expression of Concern]
Hinz M, Stein A, Uncini T
Research and Reports in Urology 2020, 12:145-146
Published Date: 23 April 2020
Amino Acid Management of Parkinson’s Disease: A Case Study [Expression of Concern]
Hinz M, Stein A, Uncini T
International Journal of General Medicine 2020, 13:145-146
Published Date: 23 April 2020
Treatment of Attention Deficit Hyperactivity Disorder with Monoamine Amino Acid Precursors and Organic Cation Transporter Assay Interpretation [Expression of Concern]
Hinz M, Stein A, Neff R, Weinberg R, Uncini T
Neuropsychiatric Disease and Treatment 2020, 16:1067-1068
Published Date: 23 April 2020
Amino Acid-Responsive Crohn’s Disease: A Case Study [Expression of Concern]
Stein A, Hinz M, Uncini T
Clinical and Experimental Gastroenterology 2020, 13:105-106
Published Date: 23 April 2020
A Pilot Study Differentiating Recurrent Major Depression from Bipolar Disorder Cycling on the Depressive Pole [Expression of Concern]
Hinz M, Stein A, Uncini T
Neuropsychiatric Disease and Treatment 2020, 16:1065-1066
Published Date: 23 April 2020
Neurotransmitter Testing of the Urine: A Comprehensive Analysis [Expression of Concern]
Hinz M, Stein A, Trachte G, Uncini T
Research and Reports in Urology 2020, 12:147-148
Published Date: 23 April 2020
The Dual-Gate Lumen Model of Renal Monoamine Transport [Expression of Concern]
Hinz M, Stein A, Uncini T
Neuropsychiatric Disease and Treatment 2020, 16:1085-1086
Published Date: 23 April 2020
Parkinson's disease managing reversible neurodegeneration [Corrigendum]
Hinz M, Stein A, Cole T, McDougall B, Westaway M
Neuropsychiatric Disease and Treatment 2016, 12:1587-1588
Published Date: 28 June 2016
Amino acid management of Parkinson's disease: a case study [Corrigendum]
Hinz M, Stein A, Uncini T
International Journal of General Medicine 2016, 9:205-206
Published Date: 13 June 2016
Parkinson’s disease managing reversible neurodegeneration
Hinz M, Stein A, Cole T, McDougall B, Westaway M
Neuropsychiatric Disease and Treatment 2016, 12:763-775
Published Date: 5 April 2016
Relative nutritional deficiencies associated with centrally acting monoamines [Corrigendum]
Hinz M, Stein A, Uncini T
International Journal of General Medicine 2015, 8:163-164
Published Date: 22 April 2015
Parkinson’s disease-associated melanin steal
Hinz M, Stein A, Cole T
Neuropsychiatric Disease and Treatment 2014, 10:2331-2337
Published Date: 10 December 2014
Parkinson's disease: carbidopa, nausea, and dyskinesia
Hinz M, Stein A, Cole T
Clinical Pharmacology: Advances and Applications 2014, 6:189-194
Published Date: 14 November 2014
The Parkinson's disease death rate: carbidopa and vitamin B6
Hinz M, Stein A, Cole T
Clinical Pharmacology: Advances and Applications 2014, 6:161-169
Published Date: 21 October 2014
Management of L-dopa overdose in the competitive inhibition state
Hinz M, Stein A, Cole T
Drug, Healthcare and Patient Safety 2014, 6:93-99
Published Date: 22 July 2014
Administration of supplemental L-tyrosine with phenelzine: a clinical literature review
Hinz M, Stein A, Cole T, Ryan P
Clinical Pharmacology: Advances and Applications 2014, 6:107-110
Published Date: 22 July 2014
5-HTP efficacy and contraindications
Hinz M, Stein A, Uncini T
Neuropsychiatric Disease and Treatment 2012, 8:323-328
Published Date: 19 July 2012
Relative nutritional deficiencies associated with centrally acting monoamines
Hinz M, Stein A, Uncini T
International Journal of General Medicine 2012, 5:413-430
Published Date: 8 May 2012
The discrediting of the monoamine hypothesis
Hinz M, Stein A, Uncini T
International Journal of General Medicine 2012, 5:135-142
Published Date: 14 February 2012
Monoamine depletion by reuptake inhibitors
Hinz M, Stein A, Uncini T
Drug, Healthcare and Patient Safety 2011, 3:69-77
Published Date: 20 October 2011
APRESS: apical regulatory super system, serotonin, and dopamine interaction
Hinz M, Stein A, Uncini T
Neuropsychiatric Disease and Treatment 2011, 7:457-463
Published Date: 5 August 2011
Validity of urinary monoamine assay sales under the “spot baseline urinary neurotransmitter testing marketing model”
Hinz M, Stein A, Uncini T
International Journal of Nephrology and Renovascular Disease 2011, 4:101-113
Published Date: 20 July 2011
Urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrine
Marty Hinz, Alvin Stein, Thomas Uncini
Research and Reports in Urology 2011, 3:19-24
Published Date: 4 February 2011
Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretation
Marty Hinz, Alvin Stein, Robert Neff, et al
Neuropsychiatric Disease and Treatment 2011, 7:31-38
Published Date: 26 January 2011
Amino acid-responsive Crohn's disease: a case study
Alvin Stein, Marty Hinz, Thomas Uncini
Clinical and Experimental Gastroenterology 2010, 3:171-177
Published Date: 6 December 2010
A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole
Marty Hinz, Alvin Stein, Thomas Uncini
Neuropsychiatric Disease and Treatment 2010, 6:741-747
Published Date: 9 November 2010
Neurotransmitter testing of the urine: a comprehensive analysis
Marty Hinz, Alvin Stein, George Trachte, et al
Research and Reports in Urology 2010, 2:177-183
Published Date: 7 October 2010
The dual-gate lumen model of renal monoamine transport
Marty Hinz, Alvin Stein, Thomas Uncini
Neuropsychiatric Disease and Treatment 2010, 6:387-392
Published Date: 5 July 2010